Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

AstraZeneca bags another cancer drug deal, this time with Inovio

AstraZeneca has clinched its third deal in less than a week to bolster its strategically important cancer drug pipeline by signing up rights to an experimental immune system-boosting medicine from Inovio Pharmaceuticals. Inovio will get $27.5 million upfront and potential future payments of up to $700 million, depending on the success of its INO-3112 immunotherapy, […]

Read More »

Sanofi teams up with Evotec, Apeiron to develop immuno-oncology pills

Sanofi is teaming up with Germany’s Evotec and Austrian biotech firm Apeiron Biologics to develop a new type of immune system-boosting cancer medicine that could be given as tablets to fight both solid tumors and blood cancers. The French drugmaker said on Monday the tie up would focus on developing small molecule-based immuno-oncology treatments, which […]

Read More »

Novavax hopes to crack elusive vaccine for common respiratory virus

A Maryland-based biotech company believes it can solve a riddle that has baffled Big Pharma for decades: how to protect against a virus that infects almost every American child. If mid-stage trial data proves positive, Novavax Inc will be closer than any drug developer to a vaccine for respiratory syncytial virus, or RSV, which affects […]

Read More »

CVS: All bets are off for new cholesterol drug contracts

CVS Health Corp, the No 2 manager of drug benefit plans for U.S. employers and insurers, will wait until a second new cholesterol-lowering drug is approved by regulators before negotiating for price discounts or adding either of the much pricier new drugs to its list of covered medications. The U.S. Food and Drug Administration in […]

Read More »

Sanofi, Evotec, Aperion Biologics Strike Collaborative Cancer Treatment Deal Worth $220 Million

Sanofi SA (SNY) has struck a partnership worth nearly $220 million with German-based Evotec AG and Austrian-based Aperion Biologics AG to develop cancer immunotherapies, the companies said this morning. The two-year deal will cover research and development efforts to advance a first-in-class small molecule-based cancer immunotherapies to treat solid and haematopoietic cancers. “Immuno-oncology has emerged […]

Read More »

Ousted Retrophin CEO Nabs $90 Million for Startup Turing Pharma

Martin Shkreli’s Turing Pharmaceuticals AG netted $90 million in Series A financing for use in advancing the company’s pipeline as well as possible M&A activity, the company announced this morning. New York-based Turing Pharmaceuticals is not sitting on the newly acquired funds. Today the company also announced that Turing acquired the U.S. rights to IMPAX […]

Read More »

Third Deal in a Week, AstraZeneca PLC Acquires Cancer Drug from Inovio Pharma for Possible $727.5 Million

UK-based AstraZeneca PLC (AZN) has been busy, announcing its third deal in the last week today, this time a licensing agreement and collaboration deal between MedImmune (AZN), AstraZeneca’s research and development arm, with Plymouth Meeting, Penn.-based Inovio Pharmaceuticals (INO). Under this new deal, MedImmune acquired exclusive rights to Inovio’s INO-3112 immunotherapy against cancers caused by […]

Read More »

Mallinckrodt Coughs Up $1.33 Billion for Therakos Inc.

Chesterfield, UK-based Mallinckrodt plc (MNK) announced it will acquire Therakos Inc. for about $1.325 billion from Los Angeles-based The Gores Group, an investment firm.   The Gores Group bought Therakos from Ortho Clinical Diagnostics, formerly a unit of Johnson & Johnson (JNJ), in December 2012. Mallinckrodt reported net sales of $2.54 billion in 2014, and […]

Read More »

Nicotine-Eating Bacteria May Lead To New Anti-Smoking Drug, The Scripps Research Institute Study

Although there is still a way to go, a team working on a new type of anti-smoking therapy based on a bacterial enzyme that devours nicotine before it can reach the brain are hopeful of success. In the Journal of the American Chemical Society, scientists from The Scripps Research Institute (TSRI) in La Jolla, CA, […]

Read More »

Thousands Of Ebola Survivors Face Severe Pain, Possible Blindness

Thousands of West Africans who were infected with the Ebola virus but survived it are suffering chronic conditions such as serious joint pain and eye inflammation that can lead to blindness, global health experts said on Friday. Ebola survivors who fought off the most severe bouts of infection are the most likely to suffer ongoing […]

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

August 2019 Focus: AI, AR/VR, Top 200 Medicines, Lions Health Takeaways, and more!


Ad Right Bottom